Previewing the ADA 82nd Annual Scientific Sessions
By Andrew Briskin
.jpg)
The diaTribe team is excited to provide you with the latest news in diabetes research, prevention, care, and technology from the American Diabetes Association 82nd Scientific Sessions. Find out which presentations we think you’ll be most excited to read about.
This week, the diaTribe team will attend the American Diabetes Association 82nd annual Scientific Sessions in New Orleans, Louisiana. We are excited to attend in-person after two years of attending virtually.
Here’s a quick look at what you can expect to read about in diaTribe Learn.
Nutrition and exercise
A summary of a June 4 session will discuss the latest evidence on the benefits of a plant-based diet and practical tips for eating with diabetes. In addition, on June 5, presentations will provide eating tips to promote heart, kidney, liver, and gut health, and prevent complications.
Other sessions will look at nutritional controversies, such as the impact of artificial sweeteners and the frequency of meals. Another session will explore how time-restricted eating and exercise can protect against obesity, liver disease, and heart disease.
The future of diabetes technology and type 1 diabetes prevention
Several sessions will cover the latest advancements in CGM, automated insulin delivery (AID), smart insulin pens, and more. This includes two June 3 sessions – one on practical tips to improve dosing adjustments using AID around meals, and another presenting new evidence suggesting that AID and CGM may be able to help optimize insulin dosing for people with type 2 diabetes.
Experts will also present the latest research on preventing or delaying type 1 diabetes, as well as islet cell replacement therapy, with two sessions on June 3 and 4 discussing the progress made to address the body’s immune response to transplanted cells, as well as a session comparing glucose management in people who have had islet transplantation vs. insulin therapy.
Latest news on diabetes medications
In the wake of the FDA approval of Mounjaro (tirzepatide), and the ample data showing the benefits of new medications like Mounjaro for treating type 2 diabetes, experts at the conference will discuss the latest evidence on medications, weight loss, and protection against complications.
Two sessions on June 6 will explore how different glucose-lowering medications can lead to weight loss and limit risk for complications – one that explores how GLP-1 receptor agonists can impact weight and heart health, and another on how SGLT-2 inhibitors and combination medications can help treat diabetes and chronic kidney disease.
To round out the conference, a June 7 session will provide an optimistic look at the future of diabetes medications, exploring the impact of Mounjaro and similar drugs known as “dual agonists” or “dual GIP/GLP-1 receptor agonists” on heart health, kidney health, and glucose management in people with type 2 diabetes.
Updates on Time in Range and CGM
Time in Range and the expanded use of CGM will be a hot topic throughout the conference. A session on June 4 led by Dr. Roy Beck will discuss the latest evidence on the impact of using Time in Range on quality of life and people’s risk for complications.
Also, sessions on June 4 and 6 will explore the expanding role of CGM in diabetes management and integrating Time in Range into electronic medical records.
In addition to the topics described above, look for additional information on mental health, how diabetes impacts the brain and cognition, women’s health and pregnancy, racial disparities and social determinants of health, and much more.
Along with our regularly-scheduled Tuesday newsletters, keep an eye out for our Sunday special-edition mailer on June 5, where we will share the most exciting news from the first days of the conference. We will follow this up with our full conference coverage, so stay tuned for more!
